Federal Register / Vol. 74, No. 48 / Friday, March 13, 2009 / Notices 10945 

listed below. This proposed information 

collection was previously published in 

the Federal Register on December 30, 

2008, page 79889–79890 and allowed 

60-days for public comment. One 

comment was received and appropriate 

response was made. The purpose of this 

notice is to allow an additional 30 days 

for public comment. The National 

Institutes of Health may not conduct or 

sponsor, and the respondent is not 

required to respond to, an information 

collection that has been extended, 

revised or implemented on or after 

October 1, 1995 unless it displays a 

current valid OMB control number. 

Proposed Collection: Title: Women’s 

Health Initiative (WHI) Observational 

Study. Type of Information Collection 

Request: REVISION: OMB No. 0925– 

0414, Expiration date: 05/31/2009. Need 

and Use of Information Collection: This 

study will be used by the NIH to 

evaluate risk factors for chronic disease 

among older women by developing and 

following a large cohort of 

postmenopausal women and relating 

subsequent disease development to 

baseline assessments of historical, 

physical, psychosocial, and physiologic 

characteristics. In addition, the 

observational study will complement 

the clinical trial (which has received 

clinical exemption) and provide 

additional information on the common 

causes of frailty, disability and death for 

postmenopausal women, namely, 

coronary heart disease, breast and 

colorectal cancer, and osteoporotic 

fractures. Continuation of follow-up 

years for ascertainment of medical 

history update forms will provide 

essential data for outcomes assessment 

for this population of aging women. 

Frequency of Response: Annually. 

Affected Public: Individuals and 

physicians. Type of Respondents: 

Women, next-of-kin, and physician’s 

office staff. The annual reporting burden 

is as follows: 

ESTIMATE OF ANNUAL HOUR BURDEN

Type of response Number of 

respondents 

Frequency of 

response 

Average hours 

per response 

Annual hour 

burden 

Observational Study Participants 63,230 1 .1 .3383 23,509 

Next of Kin1 1,163 1 .083 97 

Health Care Providers1 9 1 .083 .77 

Total 64,402 ............................ ............................ 23,607 

1Annual burden is placed on health care providers and respondent relatives/informants through requests for information which will help in the 

compilation of the number and nature of new fatal and nonfatal events. 

The annualized cost burden to 

respondents is estimated at $377,725. 

There are no Capital Costs, Operating 

Costs and/or Maintenance Costs to 

report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection is necessary for the 

proper performance of the function of 

the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Enhance the 

quality, utility, and clarity of the 

information to be collected; and (4) 

Minimize the burden of the collection of 

information on those who are to 

respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plan and instruments, contact: Shari 

Eason Ludlam, Project Officer, Women’s 

Health Initiative Program Office, 6701 

Rockledge Drive, 2 Rockledge Centre, 

Suite 10018, MSC 7936, Bethesda, MD 

20892–7936, or call (301) 402–2900 or 

E-mail your request, including your 

address to: ludlams@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: March 2, 2009. 

Michael S. Lauer, 

Director, Division of Prevention and 

Population Sciences, NHLBI, National 

Institutes of Health. 

Dated: March 3, 2009. 

Suzanne Freeman, 

Chief, FOIA, NHLBI, National Institutes of 

Health. 

[FR Doc. E9–5521 Filed 3–12–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 


sroberts on PROD1PC70 with NOTICES
10946 Federal Register / Vol. 74, No. 48 / Friday, March 13, 2009 / Notices 

Gene Signature for Predicting 

Hepatocellular Carcinoma Patient 

Prognosis 

Description of Technology: A 

progressive sequence of somatic 

mutations and epigenetic changes of 

oncogenes or tumor suppressor genes 

are believed to cause tumor 

development. However, high genomic 

instability in tumors causes the 

accumulation of genomic aberrations 

that do not contribute to tumor 

progression. Therefore it is important to 

distinguish between ‘‘driver’’ mutations 

which are functionally important and 

‘‘passenger’’ mutations which do not 

provide a selective advantage to the 

tumor cells. 

The current invention describes a 

driver gene signature for predicting 

survival in patients with hepatocellular 

carcinoma (HCC). The gene signature 

includes ten HCC-associated genes, and 

the NIH researchers further discovered 

that a decrease in DNA copy number or 

mRNA expression of some genes is 

associated with a poor prognosis in HCC 

tumors, while a decrease in DNA copy 

number or mRNA expression of a few 

other genes is associated with a good 

prognosis. 

Available for licensing is a method of 

predicting the prognosis of a patient 

diagnosed with HCC by detecting 

expression of one of more HCCassociated genes, and a method of 

identifying an agent for use in treating 

HCC. 

Applications: Prognosis for 

hepatocellular carcinoma (HCC) patient 

survival; Potential new method to 

identify therapeutic treatment for HCC 

patients. 

Market: Hepatocellular carcinoma 

(HCC) is the most frequent malignant 

tumor in the liver and the third leading 

cause of cancer death worldwide. 

Systemic chemotherapy has been shown 

to be ineffective and tumor recurrence 

rate after surgical resection is high due 

to relapse and metastasis. Therefore, the 

development of new drugs will be 

crucial to prevent relapse and to prolong 

patient survival. 

Development Status: Early-stage 

development. 

Inventors: Xin Wei Wang and 

Stephanie Roessler (NCI). 

Patent Status: U.S. Provisional 

Application No. 61/198,813 filed 10 

Nov 2008 (HHS Reference No. E–024– 

2009/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty Tong, Ph.D.; 

301–594–6565; tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Center for 

Cancer Research, Laboratory of Human 

Carcinogenesis, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Gene Signature for 

Predicting Hepatocellular Carcinoma 

Patient Prognosis. Please contact John D. 

Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Lasonolide Compounds as Reagents for 

Inducing Premature Chromosome 

Condensation and Methods of Treating 

Cancer 

Description of Technology: 

Lasonolide A is a natural product 

initially isolated from an extract of the 

shallow water Caribbean marine sponge. 

The chemical structure of lasonolide A 

was identified in 2002, and it was 

chemically synthesized in 2007. The 

current invention discloses the 

discovery that lasonolide A may be used 

as a new reagent for inducing premature 

chromosome condensation in nondividing cells; and a novel antiproliferative and anti-metastatic agent 

for cancer treatment. Currently, it is 

difficult to analyze the cytogenetic 

composition of the genome of nondividing cells because the chromosomes 

are loosely distributed in the nucleus, 

lasonolide A may be useful for 

performing cytogenetic studies in cells 

by inducing premature chromosome 

condensation without inducing mitosis. 

In addition, the invention also reveals 

that lasonolide A inhibits cancer cell 

motility. As such, lasonolide A may be 

used as an anti-cancer agent by itself or 

in combination with other anti-cancer 

agents such as inhibitors of 

topoisomerases. 

Applications: A new reagent for 

inducing premature chromosome 

condensation in non-dividing cells; a 

novel anti-cancer agent. 

Market: Cancer continues to be a 

burden to the public health of 

Americans. After heart disease, cancer is 

the most common cause of death in the 

United States. For 2008, it was 

estimated that about 565,650 Americans 

were expected to die of cancer. The 

incidence of cancer has been dropping 

over the years but it is estimated that 

over 1.4 million Americans would be 

diagnosed with cancer in 2008. 

Therefore, there is a continued need for 

the development of new therapies to 

effectively treat this disease. 

Development Status: Early-stage 

development. 

Inventors: Yves G. Pommier (NCI) et 

al. 

Patent Status: U.S. Provisional 

Application No. 61/137,193 filed 28 Jul 

2008 (HHS Reference No. E–247–2008/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty Tong, Ph.D.; 

301–594–6565; tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Center for 

Cancer Research, Laboratory of 

Molecular Pharmacology, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize Lasonolide Compounds 

as Reagents for Inducing Premature 

Chromosome Condensation and 

Methods of Treating Cancer. Please 

contact John D. Hewes, Ph.D. at 301– 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Increased Image Quality for Early 

Colon Polyp Detection 

Description of Technology: The 

invention relates to a method for 

improving the specificity and sensitivity 

of computer tomographic colonoscopy 

(CTC) computer aided detection (CAD). 

Currently CTC CAD programs are 

capable of delivering high sensitivity 

and low false positive results when used 

to detect large polyps of 1 cm or greater 

in diameter. However, CTC CAD is not 

as effective at detecting medium-sized 

polyps (6–9 mm in diameter) as it 

demonstrates lower sensitivities and 

higher false positives in this range. 

Since early polyp detection is critical to 

the survival of patients with colon 

cancer, the ability to accurately detect 

medium size polyps could be 

advantageous to the outcome of colon 

cancer treatment. 

The invention uses a wavelet-based 

analysis to distinguish true polyps from 

false positives in CTC images. The steps 

involved include generating a 2D 

projection image, computing features of 

the 2D images from their Haar wavelet 

coefficients, applying the feature 

selection algorithm, and training a 

classifier using the selected features to 

classify CTC CAD. 

Using this technology, it will be 

possible to create high quality images 

for viewing the colon surface in 3D with 

reduced false positives in the mediumsized range for colon polyps. The 

technology can also be used to locate 

anomalies in both medical and nonmedically related image applications 

such as endoscopy, microscopy, and 

photography. 

Applications: High quality images for 

early colon polyp detection; Sensitive 

and efficient colon cancer diagnosis; 

Locating anomalies in several different 

image applications. 

Development Status: Early stage. 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 48 / Friday, March 13, 2009 / Notices 10947 

Inventors: Ronald M. Summers et al. 

(CC) 

Publications: 

1. J Li, R Van Uitert, J Yao, N Petrick, 

M Franaszek, A Huang, RM Summers. 

Wavelet method for CT colonography 

computer-aided polyp detection. Med 

Phys. 2008 Aug;35(8):3527–3538. 

2. S Greenblum, J Li, A Huang, RM 

Summers. Wavelet analysis in virtual 

colonoscopy. Proc. SPIE, Vol. 6143, 

614336 (March 13, 2006); doi:10.1117/ 

12.655680. 

Patent Status: U.S. Patent Application 

No. 11/685,127 filed 12 Mar 2007 (HHS 

Reference No. E–314–2006/0–US–02); 

No foreign rights available. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Jeffrey A. James, 

Ph.D.; 301–435–5474; 

jeffreyja@mail.nih.gov. 

Microdissection and High-Throughput 

Analysis of Biological Samples 

Description of Technology: A variety 

of techniques have been used to 

microdissect specific cells or cell 

populations from a histological sample 

under direct microscopic visualization. 

Original microdissection techniques 

involved painstaking (and sometimes 

clumsy) manual dissection using 

needles or other micro-manipulation 

devices to isolate individual cells based 

on visible, histological characteristics. 

The subject technology is a method of 

performing specific target activated 

transfer from a biological sample (i.e., 

tissue) for analysis using a device 

system that can be automated for high 

throughput analysis. The method 

employs a localized reagent, such as an 

absorbative stain, that specifically 

determines the microadhesion of 

desired cellular material in a tissue 

sample to a transfer surface such as a 

thermoplastic polymer film. The energy 

from a light or heat source causes the 

microadhesion of the target cells or cell 

populations to the thermoplastic 

transfer surface. Subsequent separation 

of the film from the tissue section 

selectively removes the adhered target 

from the tissue section. The transfer 

surface is activated from within the 

target to adhere the target to the transfer 

surface, for example by heating the 

target to adhere or to a thermoplastic 

transfer surface. Such in situ activation 

can be achieved by exposing the 

biological sample to an immunoreagent 

that specifically binds to the target (or 

a component of the target). The 

immunoreagent can alter the transfer 

surface directly (for example with a heat 

generating enzyme carried by the 

immunoreagent), or indirectly (for 

example by changing a characteristic of 

the target). In some embodiments, the 

immunoreagent deposits a precipitate in 

the target that increases its light 

absorption relative to surrounding 

tissue, such that the biological specimen 

can be exposed to light to selectively 

heat the target. Alternatively, the 

immunoreagent is an 

immunofluorescent agent that carries a 

fluorophore that absorbs light and emits 

heat. 

Applications: Microdissection of 

specific cells or cell populations from a 

histological sample; High throughput 

analysis of biological samples. 

Advantages: Automated system for 

high throughput microdissection and 

analysis; Does not require a visual 

detection step. 

Development Status: In vitro data can 

be provided upon request. 

Inventors: Michael R. Emmert-Buck 

(NCI), Robert F. Bonner (NICHD), 

Michael A. Tangrea (NCI), Thomas J. 

Pohida (CIT), Rodrigo F. Chuaqui (NCI). 

Patent Status: 

International Patent Application No. 

PCT/US03/23317 filed 23 July 2003, 

which published as WO 2004/068104 

on 12 Aug 2004 (HHS Reference No. E– 

113–2003/0–PCT–02), 

U.S. Patent Application No. 10/ 

543,218 filed 22 Jul 2005 (HHS 

Reference No. E–113–2003/0–US–03), 

Canadian Patent Application No. 

2513646 filed 23 Jul 2003 (HHS 

Reference No. E–113–2003/0–CA–05), 

Australian Patent Application No. 

2003256803 filed 23 Jul 2003 (HHS 

Reference No. E–113–2003/0–AU–04), 

U.S. Patent Application No. 11/ 

202,848 filed 12 Aug 2005 (HHS 

Reference No. E–113–2003/1–US–01). 

Licensing Status: Available for 

licensing, 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018, 

changke@mail.nih.gov, 

Collaborative Research Opportunity: 

The National Cancer Institute, Center for 

Cancer Research, Laboratory of 

Pathology, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Target Activated 

Microtransfer—Expression 

Microdissection (xMD). Please contact 

John D. Hewes, Ph.D. at 301–435–3121 

or hewesj@mail.nih.gov for more 

information. 

Use of Anthrax Lethal Factor To Treat 

Cancer and Screening Methods for 

MAPK Kinase Protease Activity 

Description of Technology: Anthrax 

toxin, produced by Bacillus anthracis, is 

composed of three proteins: Protective 

antigen (PA), edema factor (EF), and 

lethal factor (LF). PA by itself has little 

or no toxic effect upon cells, but serves 

to bind cell surface receptors and 

mediate the entry of EF and LF into the 

cell. EF has been identified as an 

adenylate cyclase and together with PA 

forms a toxin (edema toxin; EdTx) 

which can induce edema formation 

when injected subcutaneously. LF and 

PA together form a toxin (lethal toxin; 

LeTx) which can cause rapid lysis of 

certain macrophage-derived cell lines in 

vitro as well as death when injected 

intravenously. 

Indirect evidence had suggested that 

LF was a metalloprotease. However, the 

intracellular target of LF remained 

unknown until recently when NIH 

scientists discovered that LF 

proteolytically inactivates mitogen 

activated protein kinase kinase 1 and 2 

(MAPKK1, 2). Using oocytes of the frog 

Xenopus laevis as well as tumor derived 

NIH3T3 (490) cells expressing an 

effector domain mutant form of the 

human V12HaRas oncogene these 

scientists demonstrated that LF induced 

proteolysis of MAPKK 1 and 2, resulting 

in their irreversible inactivation. 

MAPKK 1 and 2 are components of the 

mitogen activated protein kinase 

(MAPK) signal transduction pathway, 

an evolutionarily conserved pathway 

that controls cell proliferation and 

differentiation in response to 

extracellular signals and also plays a 

crucial role in regulating oocyte meiotic 

maturation. Further, the MAPK pathway 

has been shown to be constitutively 

activated in many primary human as 

well as in tumor-derived cell lines. 

Consistent with this, treatment of 

V12Ha-Ras transformed NIH 3T3 cells 

with LeTx inhibits cell proliferation and 

causes their reversion to a nontransformed phenotype. 

This invention specifically relates to 

in vitro and ex vivo methods of 

screening for modulators, homologues, 

and mimetics of LF mitogen activated 

protein kinase kinase (MAPKK) protease 

activity. Applications for this 

technology could be: 

• A novel tool (LF) for the study of 

the cellular role of the MAPK pathway 

in normal or tumor cells. 

• Investigation of LF for developing 

inhibitors for cancer therapy. By 

analyzing structural-functional 

relationships, additional compounds 

with improved specificity, increased 

potency, and reduced toxicity can be 

generated. Mimetics which block 

MAPKK activity or the determination of 

mechanisms of regulation of proteases 

that target MAPKK at or near the same 

site targeted by LF could be developed. 

• A protease-based assay for LF by 

using a peptide to test for LF cleavage. 


sroberts on PROD1PC70 with NOTICES
10948 Federal Register / Vol. 74, No. 48 / Friday, March 13, 2009 / Notices 

There is no commercial test for anthrax. 

This assay could be used for testing 

soldiers for anthrax exposure. 

Characterization of the interaction 

between LF and MAPKK at the amino 

acid level may lead to the generation of 

inhibitors which may prove useful in 

treating anthrax. 

Inventors: Nicholas S. Duesbery (NCI), 

Craig Webb (NCI), Stephen H. Leppla 

(NIDCR), George F. Vande Woude (NCI). 

Patent Status: 

U.S. Patent 6,485,925 issued 26 Nov 

2002 (HHS Reference No. E–068–1998/ 

0–US–06). 

U.S. Patent 6,893,835 issued 17 May 

2005 (HHS Reference No. E–068–1998/ 

0–US–07). 

U.S. Patent 6,911,203 issued 28 Jun 

2005 (HHS Reference No. E–068–1998/ 

0–US–08). 

U.S. Patent 7,056,693 issued 06 Jun 

2006 (HHS Reference No. E–068–1998/ 

0–US–10). 

U.S. Patent 7,183,071 issued 27 Feb 

2007 (HHS Reference No. E–068–1998/ 

0–US–11). 

International rights available. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Surekha Vathyam, 

Ph.D.; 301–435–4076; 

vathyams@mail.nih.gov. 

Dated: March 5, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–5418 Filed 3–12–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Orthopaedics and Skeletal Biology. 

Date: March 20, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hotel and Corporate 

Quarters, 1615 Rhode Island Avenue, NW., 

Washington, DC 20036. 

Contact Person: Daniel F. McDonald, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4110, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

1215, mcdonald@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Ligament/ 

Tendon Repair and Replacement. 

Date: March 26, 2009. 

Time: 10 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: John P. Holden, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4211, 

MSC 7814, Bethesda, MD 20892, 301–496– 

8551, holdenjo@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Review of 

HIV/AIDS Related SBIR/STTR Applications. 

Date: April 1, 2009. 

Time: 10 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Mark P. Rubert, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, BMIT/MEDI 

Member Conflict—Imaging. 

Date: April 2, 2009. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Dharam S. Dhindsa, DVM, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5110, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

1174, dhindsad@csr.nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.306, 

Comparative Medicine; 93.333, Clinical 

Research, 93.306, 93.333, 93.337, 

93.393–93.396, 93.837–93.844, 93.846– 

93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 4, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–5139 Filed 3–12–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

February 26, 2009, 8 a.m. to February 

28, 2009, 5 p.m., National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, 

MD, 20892 which was published in the 

Federal Register on February 6, 2009, 

74 FR 6292–6294. 

The meeting will be held March 25, 

2009 to March 27, 2009. The meeting 

time and location remain the same. The 

meeting is closed to the public. 

Dated: March 5, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–5344 Filed 3–12–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


sroberts on PROD1PC70 with NOTICES